IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 701–800 of 1,012

1. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
   Fumiharu Ohka, Maki Ito, Melissa Ranjit, Takeshi Senga, Ayako Motomura, Kazuya Motomura, Kaori Saito, Keiko Kato, Yukinari Kato, Toshihiko Wakabayashi et al. · 2014 · Tumor Biology
2. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults
   Jie Feng, Shuyu Hao, Changcun Pan, Yu Wang, Zhen Wu, Junting Zhang, Hai Yan, Liwei Zhang, Hong Wan · 2015 · Human Pathology
3. Phase II study of PX-866 in recurrent glioblastoma
   Marshall W. Pitz, Elizabeth A. Eisenhauer, Mary Valeria MacNeil, Brian Arthur Thiessen, Jacob C. Easaw, David R. Macdonald, David D. Eisenstat, Ankineedu Saranya Kakumanu, Muhammad Salim, Haji Ibraheem Chalchal et al. · 2015 · Neuro-Oncology
4. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
   François Lemonnier, Rob A. Cairns, Satoshi Inoue, Wanda Y. Li, Aurélie Dupuy, Sophie Broutin, Nadine Martin, Virginie Fataccioli, Romain Pelletier, Andrew C. Wakeham et al. · 2016 · Proceedings of the National Academy of Sciences
5. Mitochondria as a target in cancer treatment
   Yue Liu, Yufeng Shi · 2020 · MedComm
6. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
   Anja Karlstaedt, Javid J. Moslehi, Rudolf A. de Boer · 2022 · Nature Reviews Cardiology
7. An Epigenetic Role of Mitochondria in Cancer
   Yue Liu, Chao Chen, Xinye Wang, Yihong Sun, Jin Zhang, Juxiang Chen, Yufeng Shi · 2022 · Cells
8. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
   Jörg Felsberg, Marietta Wolter, Heike Seul, Britta Friedensdorf, Matthias Goeppert, Michael Sabel, Guido Reifenberger · 2010 · Acta Neuropathologica
9. Multi-site control and regulation of mitochondrial energy production
   Giovanni Bénard, Nadège Bellancé, Caroline José, Su Melser, Karine Nouette‐Gaulain, Rodrigue Rossignol · 2010 · Biochimica et Biophysica Acta (BBA) - Bioenergetics
10. REVIEW: MR elastography of brain tumors
    Adomas Bunevičius, Katharina Schregel, Ralph Sinkus, Alexandra J. Golby, Samuel Patz · 2019 · NeuroImage Clinical
11. IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
    Peng Zou, Haitao Xu, Pin Chen, Qing Yan, Lin Zhao, Peng Zhao, Aihua Gu · 2013 · PLoS ONE
12. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer
    Michael E. Fraser, Alejandro Berlín, Robert Glen Bristow, Theodorus van der Kwast · 2014 · Urologic Oncology Seminars and Original Investigations
13. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme
    Amparo Wolf, Sameer Agnihotri, Diana Marcela Muñoz, Abhijit Guha · 2011 · Neurobiology of Disease
14. The radiosensitivity index predicts for overall survival in glioblastoma
    Kamran A. Ahmed, Prakash Chinnaiyan, William J. Fulp, Steven A. Eschrich, Javier F. Torres–Roca, Jimmy J. Caudell · 2015 · Oncotarget
15. Non-invasive metabolic imaging of brain tumours in the era of precision medicine
    Michelle M. Kim, Abhijit Parolia, Mark P. Dunphy, Sriram Venneti · 2016 · Nature Reviews Clinical Oncology
16. Radiomics Strategy for Molecular Subtype Stratification of Lower‐Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI
    Xi Zhang, Qiang Tian, Liang Wang, Yang Liu, Baojuan Li A, Zhengrong Liang, Peng Gao, Kaizhong Zheng, Bo-feng Zhao, Hongbing Lu · 2018 · Journal of Magnetic Resonance Imaging
17. Epigenetic Targeting of Glioblastoma
    Massimo Romani, Maria Pia Pistillo, Barbara Banelli · 2018 · Frontiers in Oncology
18. PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma
    Feng Dong, Qian Li, Chao Yang, Dawei Huo, Xing Wang, Chunbo Ai, Yu Kong, Xiaoyu Sun, Wen Wang, Yan Zhou et al. · 2018 · Nature Communications
19. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H
    Bei Yang, Chen Zhong, Yingjie Peng, Zheng Lai, Jianping Ding · 2010 · Cell Research
20. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
    Jean‐Pierre Bayley, Peter Devilee · 2010 · Current Opinion in Genetics & Development
21. Molecular Genetics of Gliomas
    Christina Appin, Daniel Jay Brat · 2014 · The Cancer Journal
22. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
    Karishma Sajnani, Farhadul Islam, Robert Anthony Smith, Vinod Gopalan, Alfred King-yin Lam · 2017 · Biochimie
23. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network
    Kyu Sung Choi, Seung Hong Choi, Bumseok Jeong · 2019 · Neuro-Oncology
24. Antiangiogenic therapy for high-grade glioma
    Mustafa Khasraw, Malaka Ameratunga, Robin Grant, Helen Wheeler, Nick Pavlakis · 2014 · Cochrane Database of Systematic Reviews
25. Nuclear Exclusion of TET1 Is Associated with Loss of 5-Hydroxymethylcytosine in IDH1 Wild-Type Gliomas
    Tim Müller, Marco Gessi, Anke Waha, LJ Isselstein, Daniel Luxen, Dorothee Freihoff, Johannes Freihoff, Albert J. Becker, Matthias Simon, Jennifer Hammes et al. · 2012 · American Journal Of Pathology
26. Emerging Epigenetic Targets and Therapies in Cancer Medicine
    Relja Popovic, Jonathan D. Licht · 2012 · Cancer Discovery
27. Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2
    Aram Sandaldjian Modrek, Danielle Golub, Themasap A. Khan, Devin Bready, Jod Prado, Christopher Bowman, Jingjing Deng, Guoan Zhang, Pedro P. Rocha, Ramya Raviram et al. · 2017 · Cell Reports
28. The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma
    Fumiharu Ohka, Atsushi Natsume, Kazuya Motomura, Yugo Kishida, Yutaka Kondo, Tatsuya Abé, Yoko Nakasu, Hiroki Namba, Kenji Wakai, Takashi Fukui et al. · 2011 · PLoS ONE
29. The role of 5-hydroxymethylcytosine in human cancer
    Gerd P. Pfeifer, Wenying Xiong, Maria A. Hahn, Seung‐Gi Jin · 2014 · Cell and Tissue Research
30. Advances in the genetics of glioblastoma: are we reaching critical mass?
    Benjamin W. Purow, David Schiff · 2009 · Nature Reviews Neurology
31. Circulating glioma biomarkers
    Johan M. Kros, Dana A. M. Mustafa, Lennard J. M. Dekker, Peter A.E. Sillevis Smitt, Theodorus M. Luider, Ping‐Pin Zheng · 2014 · Neuro-Oncology
32. Molecular classification of gliomas
    Kenta Masui, Paul S. Mischel, Guido Reifenberger · 2016 · Handbook of clinical neurology
33. Hippo Signaling Pathway in Gliomas
    Konstantin Masliantsev, Lucie Karayan, Pierre‐Olivier Guichet · 2021 · Cells
34. Mutant <i>IDH</i> is sufficient to initiate enchondromatosis in mice
    Hirata, Makoto, Sasaki, Masato, Cairns, Rob A., Inoue, Satoshi, Puviindran, Vijitha, Li, Wanda Y., Snow, Bryan E., Jones, Lisa D., Wei, Qingxia, Sato, Shingo et al. · 2015 · Proceedings of the National Academy of Sciences
35. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
    Aparna Vasanthakumar, Lucy A. Godley · 2015 · Cancer Genetics
36. Classification based on mutations ofTERTpromoter andIDHcharacterizes subtypes in grade II/III gliomas
    Pei Yang, Jinquan Cai, Wei Yan, Wei Zhang, Yinyan Wang, Baoshi Chen, Guilin Li, Shouwei Li, Chenxing Wu, Kun Yao et al. · 2016 · Neuro-Oncology
37. Organ-Specific Cancer Metabolism and Its Potential for Therapy
    Ilaria Elia, Roberta Schmieder, Stefan Christen, Sarah‐Maria Fendt · 2015 · Handbook of experimental pharmacology
38. Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA
    Alexander N. Gorelick, Minsoo Kim, Walid Khaled Chatila, Konnor La, A. Ari Hakimi, Michael F. Berger, Barry S. Taylor, Payam A. Gammage, Ed Reznik · 2021 · Nature Metabolism
39. Fluorine in the Pharmaceutical Industry: FDA‐Approved Fluorine‐Containing Drugs in 2024
    Youlong Du, Yeping Bian, Daniel Baecker, Gagan Dhawan, Anas Semghouli, Lóránd Kiss, Wei Zhang, Alexander E. Sorochinsky, Vadim A. Soloshonok, Jianlin Han · 2025 · Chemistry - A European Journal
40. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
    Christopher G. Duncan, Patrick J. Killela, Cathy A. Payne, Benjamin L. Lampson, William Chen, Jeff Liu, David A. Solomon, Todd A. Waldman, Aaron J. Towers, Simon G. Gregory et al. · 2010 · Oncotarget
41. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas
    Tareq Adnan Juratli, Matthias Kirsch, Katja Robel, Silke Soucek, Kathrin D. Geiger, Rüdiger von Kummer, Gabriele Schackert, Dietmar Krex · 2012 · Journal of Neuro-Oncology
42. TET Family Proteins: Oxidation Activity, Interacting Molecules, and Functions in Diseases
    Xingyu Lu, Boxuan Simen Zhao, Chuan He · 2015 · Chemical Reviews
43. The role of mitochondria in pulmonary vascular remodeling
    Peter Dromparis, Gopinath Sutendra, Evangelos D. Michelakis · 2010 · Journal of Molecular Medicine
44. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
    Stephanie Elisabeth Combs, Stefan Rieken, Wolfgang Wick, Amir Abdollahi, Andreas von Deimling, Jürgen Debus, Christian Johannes Hartmann · 2011 · Radiation Oncology
45. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
    Sadudee Chotirat, Wanna Thongnoppakhun, Orathai Promsuwicha, Chetsada Boonthimat, Chirayu Udomsakdi Auewarakul · 2012 · Journal of Hematology & Oncology
46. Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas
    Snjezana Doğan, Deborah J. Chute, Bin Xu, Ryan N. Ptashkin, Raghu Chandramohan, Jacklyn Casanova, Khédoudja Nafa, Justin A. Bishop, Simion I. Chiosea, Edward B. Stelow et al. · 2017 · The Journal of Pathology
47. Genetic and epigenetic determinants of AML pathogenesis
    Sheng F. Cai, Ross L. Levine · 2018 · Seminars in Hematology
48. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient
    John A. Maynard, Sachi Okuchi, Stephen J. Wastling, Ayisha Al Busaidi, Ofran Almossawi, Wonder-Boy Eumane Mbatha, Sebastian Brandner, Zane Jaunmuktane, Ali Murat Koç, Laura Mancini et al. · 2020 · Radiology
49. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults
    Jessica D. Schulte, Robin Arthur Buerki, Sarah Lapointe, Annette M. Molinaro, Yalan Zhang, Javier E. Villanueva-Meyer, Arie Perry, Joanna J. Phillips, Tarık Tihan, Andrew W. Bollen et al. · 2020 · Neuro-Oncology Advances
50. The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors
    Jinghan Zhu, Yixiao Xiong, Yuxin Zhang, Jingyuan Wen, Ning Cai, Kun Cheng, Huifang Liang, Wanguang Zhang · 2020 · Oxidative Medicine and Cellular Longevity
51. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
    Shingo Takano, Wei Tian, Masahide Matsuda, Tetsuya Yamamoto, Eiichi Ishikawa, Mika Kato Kaneko, Kentaro Yamazaki, Yukinari Kato, Akira Matsumura · 2011 · Brain Tumor Pathology
52. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
    Aden Ka‐Yin Chan, Yu Yao, Zhenyu Zhang, Nellie Yuk‐Fei Chung, Joseph Shu-Ming Liu, Kay Ka‐Wai Li, Zhifeng Shi, Danny Tat Ming Chan, Wai Sang Poon, Liangfu Zhou et al. · 2014 · Modern Pathology
53. Advances in Therapeutic Cancer Vaccines
    Karrie Ka Wai Wong, Aileen W. Li, David J. Mooney, Glenn Dranoff · 2016 · Advances in immunology
54. Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges
    Junfeng Zhang, Heng Liu, Haipeng Tong, Sumei Wang, Yizeng Yang, Gang Liu, Weiguo Zhang · 2017 · Contrast Media & Molecular Imaging
55. Metabolomic signature of brain cancer
    Renu Pandey, Laura Caflisch, Alessia Lodi, Andrew Jacob Brenner, Stefano Tiziani · 2017 · Molecular Carcinogenesis
56. Mutant IDH1 Promotes Glioma Formation In Vivo
    Beatrice Philip, Diana Xuan Yu, Mark R. Silvis, Clifford Shin, James P. Robinson, Gemma L. Robinson, Adam Welker, Stephanie N. Angel, Sheryl R. Tripp, Joshua Aaron Sonnen et al. · 2018 · Cell Reports
57. CTLA-4 correlates with immune and clinical characteristics of glioma
    Fangkun Liu, Jing Huang, Xuming Liu, Quan Cheng, Chengke Luo, Zhixiong Liu · 2020 · Cancer Cell International
58. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
    Hideaki Nakajima, Hiroyoshi Kunimoto · 2014 · Cancer Science
59. Mitochondrial dysfunctions in cancer: Genetic defects and oncogenic signaling impinging on TCA cycle activity
    Enrico Desideri, Rolando Vegliante, Maria Rosa Ciriolo · 2014 · Cancer Letters
60. 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
    Jin, Genglin, Reitman, Zachary J., Spasojevic, Ivan, Batinic-Haberle, Ines, Yang, Jian, Schmidt-Kittler, Oleg, Bigner, Darell D., Yan, Hai · 2011 · PLoS ONE
61. Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
    Ruihuan Chen, Merry C. Nishimura, Samir Kharbanda, Frank Peale, Yuzhong Deng, Anneleen Daemen, William F. Forrest, Mandy Kwong, Maj Hedehus, Georgia Hatzivassiliou et al. · 2014 · Proceedings of the National Academy of Sciences
62. Molecular mechanisms in colitis-associated colorectal cancer
    Royce W. Zhou, Noam Harpaz, Steven H. Itzkowitz, Ramon E. Parsons · 2023 · Oncogenesis
63. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells
    Diane D. Mao, Amit D. Gujar, Tatenda Mahlokozera, Ishita Chen, Yanchun Pan, Jingqin Rosy Luo, Taylor M. Brost, Elizabeth A. Thompson, Alice Turski, Eric C. Leuthardt et al. · 2015 · Cell Reports
64. Establishment of age group classification for risk stratification in glioma patients
    Zhiying Lin, Runwei Yang, Kaishu Li, Guozhong Yi, Zhiyong Li, Jinglin Guo, Zhou Zhang, Peng Junxiang, Yawei Liu, Songtao Qi et al. · 2020 · BMC Neurology
65. TERT Promoter Alterations in Glioblastoma: A Systematic Review
    Nathalie Olympios, Vianney Gilard, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Maxime Fontanilles · 2021 · Cancers
66. Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of theIDH1-R132HMutation in Diffuse Glioma Biopsy Specimens
    Matthias Preusser, Adelheid Wöehrer, Susanne Stary, Romana Höftberger, Berthold Streubel, Johannes Andreas Hainfellner · 2011 · Journal of Neuropathology & Experimental Neurology
67. Pheochromocytomas: The (pseudo)-hypoxia hypothesis
    Judith Favier, Anne‐Paule Gimenez‐Roqueplo · 2010 · Best Practice & Research Clinical Endocrinology & Metabolism
68. On Getting There from Here
    Steven Lanier McKnight · 2010 · Science
69. LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
    Roseli da Silva, Miyuki Uno, Suely Kazue Nagahashi Marie, Sueli Mieko Oba‐Shinjo · 2015 · PLoS ONE
70. Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism
    Paolo Ettore Porporato, Valéry L. Payen, Bjorn Baselet, Pierre Sonveaux · 2015 · Cellular and Molecular Life Sciences
71. Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
    Bozena Kaminska, Bartosz Czapski, Rafał Guzik, Sylwia Katarzyna Król, Bartłomiej Gielniewski · 2019 · Molecules
72. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
    Erik Ladomersky, Lijie Zhai, Kristen L. Lauing, April Bell, Jiahui Xu, Masha Kocherginsky, Bin Zhang, Jennifer D. Wu, Joseph R. Podojil, Leonidas C. Platanias et al. · 2020 · Clinical Cancer Research
73. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis
    Sandra Ines Camelo-Piragua, Michael Jansen, Aniruddha Ganguly, J. ChulMin Kim, David N. Louis, Catherine L. Nutt · 2009 · Acta Neuropathologica
74. Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges
    David A. Reardon, Patrick Yung Wen, Ingo K. Mellinghoff · 2014 · Neuro-Oncology
75. A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG
    Beth Pietrak, Huizhen Zhao, Hongwei Qi, Chad J. Quinn, Enoch N. Gao, Joseph G. Boyer, N.O. Concha, Kristin Brown, Chaya Duraiswami, Richard F. Wooster et al. · 2011 · Biochemistry
76. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
    Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez, Carlos Mesía, Sonia Del Barco, Estela Pineda, José Muñoz-Langa, Anna Estival, Ramón de las Peñas, J. Fuster et al. · 2020 · Neuro-Oncology
77. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
    Kristen A. Batich, Duane A. Mitchell, Patrick N Healy, James E. Herndon, John Howard Sampson · 2020 · Clinical Cancer Research
78. Nontargeted Elucidation of Metabolic Pathways Using Stable-Isotope Tracers and Mass Spectrometry
    Karsten Hiller, Christian M. Metallo, Joanne K. Kelleher, Gregory N Stephanopoulos · 2010 · Analytical Chemistry
79. PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH 1 Mutant Glioblastoma
    Joanna J. Phillips, Derick Aranda, David W. Ellison, Alexander Russell Judkins, Sidney E. Croul, Daniel Jay Brat, Keith Lloyd Ligon, Craig Horbinski, Sriram Venneti, Gelareh Mohammed Zadeh et al. · 2013 · Brain Pathology
80. Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations
    Lucie Evenepoel, Thomas G. Papathomas, Niels M. G. Krol, Esther Korpershoek, Ronald R. de Krijger, Alexandre Persu, Winand N.M. Dinjens · 2014 · Genetics in Medicine
81. Targeting glucose metabolism in patients with cancer
    Shannon Elf, Jing Chen · 2013 · Cancer
82. Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
    Hideho Okada, Lisa Helene Butterfield, Ronald L. Hamilton, Aki Hoji, Masashi Sakaki, Brian J. Ahn, Gary Kohanbash, Jan Drappatz, Johnathan A. Engh, Nduka Amankulor et al. · 2014 · Clinical Cancer Research
83. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
    Remco Jurriaan Molenaar, Tomas Radivoyevitch, Yasunobu Nagata, Mohammed Khurshed, Bartolomiej Przychodzen, Hideki Makishima, Mingjiang Xu, Fonnet E. Bleeker, Johanna W. Wilmink, Hetty E. Carraway et al. · 2018 · Clinical Cancer Research
84. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
    Xiaoyan Liu, Yuping Gong · 2019 · Biomarker Research
85. Glioma and temozolomide induced alterations in gut microbiome
    Anthony Patrizz, Antonio Dono, Soheil Zorofchian, Gabriella Hines, Takeshi Takayasu, Nuruddin Husein, Yoshihiro Otani, Octavio Arevalo, Huimahn Alex Choi, Jude P. J. Savarraj et al. · 2020 · Scientific Reports
86. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
    Anh Nhi Tran, Albert Lai, S. Li, Whitney B. Pope, S. Teixeira, Robert J. Harris, Davis C. Woodworth, Phioanh Leia Nghiemphu, Timothy Francis Cloughesy, Benjamin M. Ellingson · 2013 · Neuro-Oncology
87. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
    Sebastian Brandner, Andreas von Deimling · 2015 · Neuropathology and Applied Neurobiology
88. Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies
    Kenta Masui, Timothy Francis Cloughesy, Paul S. Mischel · 2011 · Neuropathology and Applied Neurobiology
89. Current perspectives between metabolic syndrome and cancer
    Carla Micucci, Debora Valli, Giulia Matacchione, Alfonso Catalano · 2016 · Oncotarget
90. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
    For POLA Network, Émeline Tabouret, Anh Tuấn Nguyễn, Caroline Dehais, Catherine Carpentier, François Ducray, Ahmed Idbaïh, Karima Mokhtari, Anne Jouvet, Emmanuelle Uro‐Coste et al. · 2016 · Acta Neuropathologica
91. Advances in Immunotherapy for Glioblastoma Multiforme
    Boyuan Huang, Hongbo Zhang, Lijuan Gu, Bainxin Ye, Zhihong Jian, Creed M. Stary, Xiaoxing Xiong · 2017 · Journal of Immunology Research
92. MR Elastography Analysis of Glioma Stiffness andIDH1-Mutation Status
    Kay M. Pepin, Kiaran P. McGee, Arvin Arani, David S. Lake, Kevin J. Glaser, Armando Manduca, Ian F. Parney, Richard L. Ehman, John Huston · 2017 · American Journal of Neuroradiology
93. Management of low-grade glioma: a systematic review and meta-analysis
    Timothy J. Brown, Daniela Annenelie Bota, Martin J. van den Bent, Paul D. Brown, Elizabeth Anne Maher, Dawit Gebremichael Aregawi, Linda M. Liau, Jan C. Buckner, Michael Weller, Mitchel Stuart Berger et al. · 2018 · Neuro-Oncology Practice
94. Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.
    Nadine Darwiche · 2020 · PubMed Central
95. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
    Abigail Kora Suwala, Damian Stichel, Daniel Schrimpf, Matthias Kloor, Annika K. Wefers, Annekathrin Reinhardt, Sybren L. N. Maas, Christian Peter Kratz, Leonille Schweizer, Martin Hasselblatt et al. · 2020 · Acta Neuropathologica
96. Epigenetics and cancer metabolism
    Christelle Johnson, Marc O. Warmoes, Xiling Shen, Jason W. Locasale · 2013 · Cancer Letters
97. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato, Genglin Jin, Chien-Tsun Kuan, Roger E. McLendon, Hai Yan, Darell D. Bigner · 2009 · Biochemical and Biophysical Research Communications
98. Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine
    Houman Sotoudeh, Omid Shafaat, Joshua D. Bernstock, Michael David Brooks, Galal Elsayed, Jason Chen, Paul Szerip, Gustavo Chagoya, Florian A Gessler, Ehsan Sotoudeh et al. · 2019 · Frontiers in Oncology
99. C6 cell line: the gold standard in glioma research.
    Dimitrios Giakoumettis, Aristeidis Κritis, Nikolaos Foroglou · 2018 · PubMed Central
100. The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
     Katarína Smolková, Petr Ježek · 2012 · International Journal of Cell Biology